Skip to main content

Advertisement

SpringerLink
Log in
Menu
Find a journal Publish with us Track your research
Search
Cart
  1. Home
  2. Current Treatment Options in Oncology
  3. Article

Human papillomavirus therapy for the prevention and treatment of cervical cancer

  • Published: April 2003
  • Volume 4, pages 111–119, (2003)
  • Cite this article
Download PDF
Current Treatment Options in Oncology Aims and scope Submit manuscript
Human papillomavirus therapy for the prevention and treatment of cervical cancer
Download PDF
  • Samir N. Khleif MD1 

  • 113 Accesses

  • 1 Citation

  • Explore all metrics

Opinion statement

Cervical carcinoma is associated with human papillomavirus infection. Proliferation of cancer cells depends on the continual expression of the E6 and E7 viral oncogenes. This article includes treatment strategies that can interfere with expression or function of the proteins and immunotherapeutic approaches that can eliminate cells that express E6 and E7 proteins.

Article PDF

Download to read the full article text

Similar content being viewed by others

Advances in Cervical Cancer and Ongoing Clinical Trials

Chapter © 2016

Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy

Article 13 July 2019

Aristocratic human papillomavirus drove cervical cancer: a study of the therapeutic potential of the combination of interferon with zinc

Article 24 October 2020
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

References and Recommended Reading

  1. Alani RM, Munger K: Human papillomaviruses and associated malignancies. J Clin Oncol 1998, 16:330–337. A review of the mechanism by which the human papillomavirus exerts its transformation effect on the cervical epethilium. The article also provides the background to understand the therapeutic strategies that are described in the review.

    PubMed  CAS  Google Scholar 

  2. Kirnbauer R, Booy F, Cheng N, et al.: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180–12184.

    Article  PubMed  CAS  Google Scholar 

  3. Dvoretzky I, Shober R, Chattopadhyay SK, Lowy DR: A quantitative in vitro focus assay for bovine papilloma virus. Virology 1980, 103:369–375.

    Article  PubMed  CAS  Google Scholar 

  4. Lowy DR, Schiller JT: Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta 1999, 1423:M1-M8.

    PubMed  CAS  Google Scholar 

  5. Volpers C, Schirmacher P, Streeck RE, Sapp M: Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994, 200:504–512.

    Article  PubMed  CAS  Google Scholar 

  6. Roden RB, Hubbert NL, Kirnbauer R, et al.: Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996, 70:3298–3301.

    PubMed  CAS  Google Scholar 

  7. Kirnbauer R, Taub J, Greenstone H, et al.: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67:6929–6936.

    PubMed  CAS  Google Scholar 

  8. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al.: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92:11553–11557.

    Article  PubMed  CAS  Google Scholar 

  9. Jansen KU, Rosolowsky M, Schultz LD, et al.: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995, 13:1509–1514.

    Article  PubMed  CAS  Google Scholar 

  10. Breitburd F, Kirnbauer R, Hubbert NL, et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959–3963.

    PubMed  CAS  Google Scholar 

  11. Schiller JT, Lowy DR: Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 2001, 1:571–581. An important review that presents the concept of virus-like particles and its use for the prevention of human papillomavirus (HPV) infection, the main strategy that is used for this purpose.

    Article  PubMed  CAS  Google Scholar 

  12. Da Silva DM, Velders MP, Nieland JD, et al.: Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol 2001, 13:633–641.

    Article  PubMed  Google Scholar 

  13. Harro CD, Pang YY, Roden RB, et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93:284–292.

    Article  PubMed  CAS  Google Scholar 

  14. Schiller J, Lowy D: Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001:50-54.

  15. Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645–1651. The first controlled trial that shows efficacy of HPV prevention in humans. The importance of this paper is that it is a proof of principle that this strategy may be able to prevent an infection of an oncogenic agent.

    Article  PubMed  CAS  Google Scholar 

  16. Nardelli-Haefliger D, Roden R, Balmelli C, et al.: Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 1999, 73:9609–9613.

    PubMed  CAS  Google Scholar 

  17. Dupuy C, Buzoni-Gatel D, Touze A, et al.: Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999, 73:9063–9071.

    PubMed  CAS  Google Scholar 

  18. Schreckenbergerab C, Sethupathia P, Kanjanahaluethaia A, et al.: Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine 2000, 19:227–233.

    Article  Google Scholar 

  19. Valdez Graham V, Sutter G, Jose MV, et al.: Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000, 88:1650–1662.

    Article  Google Scholar 

  20. Rosales C, Graham VV, Rosas GA, et al.: A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 2000, 49:347–360. The paper exhibits an example of how to use the pathway of cell cycle inhibition of the HPV and the integration of the virus into the human cell genome for therapy. The paper includes an example of using gene therapy effectively in the down-regulation of E6 and E7 transcription.

    Article  PubMed  CAS  Google Scholar 

  21. Jin L, Qi M, Chen DZ, et al.: Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 1999, 59:3991–3997.

    PubMed  CAS  Google Scholar 

  22. Kamradt MC, Mohideen N, Vaughan AT: RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 2000, 77:177–182.

    Article  PubMed  CAS  Google Scholar 

  23. Maehama T, Patzelt A, Lengert M, et al.: Selective downregulation of human papillomavirus transcription by 2-deoxyglucose. Int J Cancer 1998, 76:639–646.

    Article  PubMed  CAS  Google Scholar 

  24. Narayanan BA, Holladay EB, Nixon DW, Mauro CT: The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV16 E6/E7 mRNA and cell cycle in cervical carcinoma cells. Life Sci 1998, 63:565–573.

    Article  PubMed  CAS  Google Scholar 

  25. Hietanen S, Lain S, Krausz E, et al.: Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A 2000, 97:8501–8506.

    Article  PubMed  CAS  Google Scholar 

  26. Scribner DR Jr, Benbrook DM: Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol 2002, 85:223–225.

    Article  PubMed  CAS  Google Scholar 

  27. Follen M, Atkinson EN, Schottenfeld D, et al.: A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001, 7:3356–3365.

    PubMed  CAS  Google Scholar 

  28. Wadler S, Schwartz EL, Anderson P, et al.: Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. Cancer J Sci Am 1999, 5:165–170.

    PubMed  CAS  Google Scholar 

  29. DeLong R, Nolting A, Fisher M, et al.: Comparative pharmakokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleatide in nude mice. Antisense Nucleic Acid Drug Dev 1997, 7:71–77.

    PubMed  CAS  Google Scholar 

  30. Crook T, Tidy JA, Vousden KH: Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67:547–556.

    Article  PubMed  CAS  Google Scholar 

  31. Green DW, Roh H, Pippin J, Drebin JA: Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. J Am Coll Surg 2000, 191:93–105.

    Article  PubMed  CAS  Google Scholar 

  32. Hamada K, Sakaue M, Alemany R, et al.: Adenovirusmediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996, 63:219–227.

    Article  PubMed  CAS  Google Scholar 

  33. He Z, Wlazlo AP, Kowalczyk DW, et al.: Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000, 270:146–161.

    Article  PubMed  CAS  Google Scholar 

  34. Alvarez-Salas LM, Arpawong TE, DiPaolo JA: Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense Nucleic Acid Drug Dev 1999, 9:441–450. The article provides an example of the strategy that is directed at the inhibition of the translation of E6/E7 mRNA by antisense technology.

    PubMed  CAS  Google Scholar 

  35. Cotten M, Birnstiel ML: Ribozyme mediated destruction of RNA in vivo. Embo J 1989, 8:3861–3866.

    PubMed  CAS  Google Scholar 

  36. Shippy R, Lockner R, Farnsworth M, Hampel A: The hairpin ribozyme. Discovery, mechanism, and development for gene therapy. Mol Biotechnol 1999, 12:117–129.

    Article  PubMed  CAS  Google Scholar 

  37. Alvarez-Salas LM, Cullinan AE, Siwkowski A, et al.: Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci U S A 1998, 95:1189–1194.

    Article  PubMed  CAS  Google Scholar 

  38. Chen PW, Wang M, Bronte V, et al.: Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996, 156:224–231.

    PubMed  CAS  Google Scholar 

  39. Phelps WC, Barnes JA, Lobe DC: Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antivir Chem Chemother 1998, 9:359–377.

    PubMed  CAS  Google Scholar 

  40. Butz K, Denk C, Ullmann A, et al.: Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 2000, 97:6693–6697.

    Article  PubMed  CAS  Google Scholar 

  41. Beerheide W, Bernard HU, Tan YJ, et al.: Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst 1999, 91:1211–1220.

    Article  PubMed  CAS  Google Scholar 

  42. Hamada K, Alemany R, Zhang WW, et al.: Adenovirusmediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996, 56:3047–3054.

    PubMed  CAS  Google Scholar 

  43. Bischoff JR, Kirn DH, Williams A, et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373–376.

    Article  PubMed  CAS  Google Scholar 

  44. Lane DP: Killing tumor cells with viruses: a question of specificity. Nat Med 1998, 4:1012–1013.

    Article  PubMed  CAS  Google Scholar 

  45. Heise C, Sampson-Johannes A, Williams A, et al.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997, 3:639–645.

    Article  PubMed  CAS  Google Scholar 

  46. Kirn D, Hermiston T, McCormick F: ONYX-015: clinical data are encouraging. Nat Med 1998, 4:1341–1342.

    Article  PubMed  CAS  Google Scholar 

  47. Nemunaitis J, Cunningham C, Buchanan A, et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001, 8:746–759.

    Article  PubMed  CAS  Google Scholar 

  48. Vasey PA, Shulman LN, Campos S, et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-genedeleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J Clin Oncol 2002, 20:1562–1569.

    Article  PubMed  CAS  Google Scholar 

  49. Nemunaitis J, Ganly I, Khuri F, et al.: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000, 60:6359–6366.

    PubMed  CAS  Google Scholar 

  50. Lamont JP, Nemunaitis J, Kuhn JA, et al.: A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000, 7:588–592.

    PubMed  CAS  Google Scholar 

  51. Onyx plans phase III trial of ONYX-015 for head & neck cancer. Oncologist 1999, 4:432.

  52. Kadish AS, Ho GY, Burk RD, et al.: Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997, 89:1285–1293.

    Article  PubMed  CAS  Google Scholar 

  53. Evans EM, Man S, Evans AS, Borysiewicz LK: Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997, 57:2943–2950.

    PubMed  CAS  Google Scholar 

  54. Alexander M, Salgaller ML, Celis E, et al.: Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996, 175:1586–1593.

    Article  PubMed  CAS  Google Scholar 

  55. Chu NR, Wu HB, Wu T, et al.: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000, 121:216–225.

    Article  PubMed  CAS  Google Scholar 

  56. Chen CH, Wang TL, Hung CF, et al.: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60:1035–1042.

    PubMed  CAS  Google Scholar 

  57. Liu DW, Tsao YP, Kung JT, et al.: Recombinant adenoassociated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000, 74:2888–2894.

    Article  PubMed  CAS  Google Scholar 

  58. Greenstone HL, Nieland JD, de Visser KE, et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV-16 tumor model. Proc Natl Acad Sci U S A 1998, 95:1800–1805.

    Article  PubMed  CAS  Google Scholar 

  59. Mayordomo JI, Zorina T, Storkus WJ, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1:1297–1302.

    Article  PubMed  CAS  Google Scholar 

  60. Cheever MA, Chen W: Therapy with cultured T cells: principles revisited. Immunol Rev 1997, 157:177–194.

    Article  PubMed  CAS  Google Scholar 

  61. Boursnell ME, Rutherford E, Hickling JK, et al.: Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996, 14:1485–1494.

    Article  PubMed  CAS  Google Scholar 

  62. Chen CH, Ji H, Suh KW, et al.: Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type-16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999, 6:1972–1981.

    Article  PubMed  CAS  Google Scholar 

  63. Borysiewicz LK, Fiander A, Nimako M, et al.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347:1523–1527. The paper includes examples of HPV-vaccine clinical trials and different methods of vaccination and proof of principal of the immunologic efficacy of HPV-E7 vaccination when used in various antigen forms.

    Article  PubMed  CAS  Google Scholar 

  64. Steller MA, Gurski KJ, Murakami M, et al.: Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type-16 E7. Clin Cancer Res 1998, 4:2103–2109. The paper includes examples of HPV-vaccine clinical trials and different methods of vaccination and proof of principal of the immunologic efficacy of HPV-E7 vaccination when used in various antigen forms.

    PubMed  CAS  Google Scholar 

  65. van Driel WJ, Ressing ME, Kenter GG, et al.: Vaccination with HPV-16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999, 35:946–952. The paper includes examples of HPV-vaccine clinical trials and different methods of vaccination and proof of principal of the immunologic efficacy of HPV-E7 vaccination when used in various antigen forms.

    Article  PubMed  Google Scholar 

  66. Wojtowicz M, Hamilton JM, Khong H, et al.: Vaccination of Cervical Cancer Patients with Papillomavirus Type-16 E6 and E7 Peptides. Atlanta, GA: American Society of Clinical Oncology; 1999.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Building 8, Room 4137, 20892, Bethesda, MD, USA

    Samir N. Khleif MD

Authors
  1. Samir N. Khleif MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khleif, S.N. Human papillomavirus therapy for the prevention and treatment of cervical cancer. Curr. Treat. Options in Oncol. 4, 111–119 (2003). https://doi.org/10.1007/s11864-003-0012-0

Download citation

  • Issue Date: April 2003

  • DOI: https://doi.org/10.1007/s11864-003-0012-0

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Cervical Cancer
  • Cervical Cancer Cell
  • Recombinant Vaccinia Virus
  • Cervical Intraepithelial Neoplasia
  • Hairpin Ribozyme
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our imprints

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Cancel contracts here

35.173.48.18

Not affiliated

Springer Nature

© 2024 Springer Nature